IMCD: From Dutch Trading House Spin-off to Global Specialty Chemicals Formulation Distribution Machine

Origin

In 1995, Piet van der Slikke (a former lawyer) and Hans Kooijmans (a former CPA and CFO) spun off the chemical distribution assets of the Dutch conglomerate Internatio-Müller, which were scattered across the Benelux region, France, Australia, and New Zealand, into an independent division headquartered in Rotterdam. They realized that traditional trading houses relied on thin margins and high cyclicality, whereas the real opportunity lay in specialty chemicals and food ingredients—where customers demand formulation expertise and technical support rather than simple logistics. In 2001, management partnered with private equity to buy out the parent company's assets and rebranded as IMCD. Since then, they have used a dual-engine strategy of M&A and organic growth to transform a regional distribution business into a global platform.

Milestones

Turning Points

• 2001: Management buyout with private equity and rebranding to IMCD, transitioning from a subsidiary to an independent operator.
• 2011: Bain Capital acquisition established external M&A as the primary growth engine, expanding globalization from Europe to the Americas, Asia-Pacific, and Latin America.
• 2014: IPO on Euronext Amsterdam at €21 per share, providing public market capital as a war chest for continuous M&A.
• 2019: Promotion to the AEX blue-chip index, gaining institutional funding and brand credibility, which enhanced bargaining power when acquiring smaller distributors.
• 2023-2024: Generational leadership transition from the founding CEO to professional management, with the M&A machine maintaining its operational momentum.

Failures & Pitfalls

• CFO Hans Kooijmans publicly admitted that commercial synergies (cross-selling, supplier sharing) for certain acquisitions were slower than expected or not fully realized, highlighting a persistent gap between acquisition promises and execution.
• Integrating corporate culture and unifying IT systems remains a long-term challenge when frequently acquiring global family-owned or regional distributors, often causing friction between the entrepreneurial spirit of the acquired teams and the group's control processes.
• Global supply chain disruptions in the early 2020s and geopolitical conflicts/currency volatility in Iran in Q1 2026 repeatedly impacted the chemical distribution industry, as price pass-throughs to downstream customers consistently lagged behind upstream cost increases.
• Competition with other large private equity firms for high-quality targets has driven up acquisition valuations, putting pressure on transaction returns in certain years and forcing the company to use stricter screening discipline to hedge against bidding risks.

Core Data

• 2025 Full-Year Revenue：€4.779 billion (5% YoY growth at constant exchange rates) (Company disclosure, as of 2026, unaudited)
• 2025 Full-Year Gross Profit：€1.194 billion (Company disclosure, as of 2026, unaudited)
• 2025 Operating EBITA：€498 million (Company disclosure, as of 2026, unaudited)
• Employee Count：Approx. 5,246 (Company disclosure, as of 2026, unaudited)
• Active Customers：Over 71,000 (Company disclosure, as of 2026, unaudited)
• Number of Suppliers：3,000 (Company disclosure, as of 2026, unaudited)
• Product Portfolio：Over 52,000 (Company disclosure, as of 2026, unaudited)
• Cumulative Acquisitions：Over 150 (1995-2026, averaging 7+ per year in the last 5 years) (Company disclosure, as of 2026, unaudited)
• IPO Issue Price：€21 (2014, Euronext Amsterdam) (Company disclosure, as of 2026, unaudited)

Competitors / Peers

Key global competitors in specialty chemical distribution include Brenntag (Germany, the world's largest chemical distributor, which acquired Univar Solutions in 2023), Azelis (Belgium, sharing the same formulation distribution model), and Biesterfeld (Germany). Production companies with self-built distribution networks, such as Nouryon, also pose indirect competition. Compared to Brenntag's bulk-scale approach, IMCD's strategy is most similar to Azelis, both excelling through technical laboratories and high-frequency M&A. IMCD continues to capture market share in specialty and food ingredient segments through its 80+ laboratories and a pace of 7+ deals per year, with competition for Asian and nutritional ingredient targets expected to intensify.